Top drugs maker Pfizer Inc. will be very happy to enter the New Year of 2012 as America’s health regulators approved a new generation of pneumococcal vaccine called Prevnar. The new vaccine is catered for adults aged 50 and older to fight pneumonia, meningitis and other sickness. The vaccine is manufactured by Wyeth Pharmaceuticals Inc., and marketed worldwide by Pfizer Inc.
With growing number of retiring baby boomers generation aged 50+ in America, the new vaccine could help Pfizer Inc. to generate more revenues in years to come. According to reuters.com, the annual sales of Prevnar could reach at a minimum of $1.5 billion per year.
While America’s health regulator just approved the new vaccine before the New Year eve of 2012, lawmakers in several countries have approved the vaccine for use in adults aged 50 and older. As per reuters.com, countries that have approved the vaccine including the European Union, Australia, some South America countries (incl. Bolivia, Colombia, Ecuador), and some South East Asian countries (incl. Thailand and the Philippines).
(Images: Pfizer Inc. Prevnar)